Dicloxacillin Sodium
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Dicloxacillin Sodium
- Generic name
- DICLOXACILLIN SODIUM
- Manufacturer
- Asclemed USA, Inc.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- a4174fda-68f7-4834-be58-dd6b167cf9f0
- SPL ID
- b41444ca-246e-b54e-e053-2a95a90ae0e7
- Version
- 1
- Effective date
- 2020-11-14
- Source export date
- 2026-09-28
- Source partition
- 11
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0011-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/aa96b5a2be6b394393acd0090f6948bdf99e0e8e00666f81608929c8fa83db77/drug-label-0011-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 06:14:34
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 062286 | derived:openfda.application_number |
| application number | ANDA062286 | openfda.application_number | |
| brand name | Dicloxacillin Sodium | openfda.brand_name | |
| generic name | DICLOXACILLIN SODIUM | openfda.generic_name | |
| manufacturer name | Asclemed USA, Inc. | openfda.manufacturer_name | |
| ndc | package | 76420-183-20 | openfda.package_ndc |
| ndc | product | 76420-183 | openfda.product_ndc |
| ndc11 | package | 76420018320 | derived:openfda.package_ndc |
| rxcui | 197596 | openfda.rxcui | |
| spl id | b41444ca-246e-b54e-e053-2a95a90ae0e7 | id | |
| spl set id | a4174fda-68f7-4834-be58-dd6b167cf9f0 | set_id | |
| unii | 4HZT2V9KX0 | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS Serious and occasionally fatal hypersensitivity (anaphylactic shock with collapse) reactions have occurred in patients receiving penicillin. The incidence of anaphylactic shock in all penicillin-treated patients is between 0.015% and 0.04%. Anaphylactic shock resulting in death has occurred in approximately 0.002% of the patients treated. Although anaphylaxis is more frequent following a parenteral administration, it has occurred in patients receiving oral penicillins. When penicillin therapy is indicated, it should be initiated only after a comprehensive patient drug and allergy history has been obtained. If an allergic reaction occurs, the drug should be discontinued and the patient should receive supportive treatment, e.g., artificial maintenance of ventilation, pressor amines, antihistamines and corticosteroids. Individuals with a history of penicillin hypersensitivity may also experience allergic reactions when treated with a cephalosporin.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS Body as a Whole The reported incidence of allergic reactions to penicillin ranges from 0.7% to 10% (see WARNINGS ). Sensitization is usually the result of treatment, but some individuals have had immediate reactions to penicillin when first treated. In such cases, it is thought that the patients may have had prior exposure to the drug via trace amounts present in milk and vaccines. Two types of allergic reactions to penicillin are noted clinically, immediate and delayed. Immediate reactions usually occur within 20 minutes of administration and range in severity from urticaria and pruritus to angioneurotic edema, laryngospasm, bronchospasm, hypotension, vascular collapse and death. Such immediate anaphylactic reactions are very rare (see WARNINGS ) and usually occur after parenteral therapy, but have occurred in patients receiving oral therapy. Another type of immediate reaction, an accelerated reaction, may occur between 20 minutes and 48 hours after administration and may include urticaria, pruritus and fever. Although laryngeal edema, laryngospasm and hypotension occasionally occur, fatality is uncommon. Delayed allergic reactions to penicillin therapy usually occur after 48 hours and sometimes as late as two to four weeks after initiation of therapy. Manifestations of this type of reaction include serum sickness-like symptoms (i.e., fever, malaise, urticaria, myalgia, arthralgia, abdominal pain) and various skin rashes. Nausea, vomiting, diarrhea, stomatitis, black or hairy tongue and other symptoms of gastrointestinal irritation may occur, especially during oral penicillin therapy. Nervous System Reactions Neurotoxic reactions similar to those observed with penicillin G may occur with large intravenous doses of the penicillinase-resistant penicillins, especially with patients with renal insufficiency. Urogenital Reactions Renal tubular damage and interstitial nephritis have been associated with the administration of methicillin sodium and, infrequently, with the administration of nafcillin and oxacillin. Manifestations of this reaction may include rash, fever, eosinophilia, hematuria, proteinuria and renal insufficiency. Methicillin-induced nephropathy does not appear to be dose-related and is generally reversible upon prompt discontinuation of therapy. Metabolic Reactions Agranulocytosis, neutropenia and bone marrow depression have been associated with the use of methicillin sodium and nafcillin. Hepatotoxicity, characterized by fever, nausea and vomiting associated with abnormal liver function tests, mainly elevated SGOT levels, has been associated with the use of oxacillin. RECOMMENDED DOSAGES FOR DICLOXACILLIN IN MILD TO MODERATE AND SEVERE INFECTIONS DRUG ADULTS CHILDREN Mild to Moderate Severe Mild to Moderate Severe Dicloxacillin 125 mg every 250 mg every 12.5 mg/kg/day 1 25 mg/kg/day 1 6 hours 6 hours in equally in equally divided doses divided doses every 6 hours every 6 hours 1. Patients weighing less than 40 kg (88 lbs)
adverse reactions table
<table><caption>RECOMMENDED DOSAGES FOR DICLOXACILLIN IN MILD TO MODERATE AND SEVERE INFECTIONS </caption><col width="14%"/><col width="19%"/><col width="15%"/><col width="19%"/><col width="16%"/><tbody><tr><td styleCode=" Botrule Toprule Lrule " valign="top"><paragraph>DRUG</paragraph></td><td align="center" colspan="2" styleCode=" Botrule Toprule Lrule " valign="top"><paragraph>ADULTS</paragraph></td><td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule " valign="top"><paragraph>CHILDREN</paragraph></td></tr><tr><td styleCode=" Botrule Lrule " valign="top"/><td styleCode=" Botrule Lrule " valign="top"><paragraph>Mild to Moderate</paragraph></td><td styleCode=" Botrule Lrule " valign="top"><paragraph>Severe</paragraph></td><td styleCode=" Botrule Lrule " valign="top"><paragraph>Mild to Moderate</paragraph></td><td styleCode=" Botrule Lrule Rrule " valign="top"><paragraph>Severe</paragraph></td></tr><tr><td styleCode=" Botrule Lrule " valign="top"><paragraph>Dicloxacillin</paragraph></td><td styleCode=" Botrule Lrule " valign="top"><paragraph>125 mg every</paragraph></td><td styleCode=" Botrule Lrule " valign="top"><paragraph>250 mg every</paragraph></td><td styleCode=" Botrule Lrule " valign="top"><paragraph>12.5 mg/kg/day <sup>1</sup></paragraph></td><td styleCode=" Botrule Lrule Rrule " valign="top"><paragraph>25 mg/kg/day <sup>1</sup></paragraph></td></tr><tr><td styleCode=" Botrule Lrule " valign="top"/><td styleCode=" Botrule Lrule " valign="top"><paragraph>6 hours</paragraph></td><td styleCode=" Botrule Lrule " valign="top"><paragraph>6 hours</paragraph></td><td styleCode=" Botrule Lrule " valign="top"><paragraph>in equally</paragraph></td><td styleCode=" Botrule Lrule Rrule " valign="top"><paragraph>in equally</paragraph></td></tr><tr><td styleCode=" Botrule Lrule " valign="top"/><td styleCode=" Botrule Lrule " valign="top"/><td styleCode=" Botrule Lrule " valign="top"/><td styleCode=" Botrule Lrule " valign="top"><paragraph>divided doses</paragraph></td><td styleCode=" Botrule Lrule Rrule " valign="top"><paragraph>divided doses</paragraph></td></tr><tr><td styleCode=" Botrule Lrule " valign="top"/><td styleCode=" Botrule Lrule " valign="top"/><td styleCode=" Botrule Lrule " valign="top"/><td styleCode=" Botrule Lrule " valign="top"><paragraph>every 6 hours</paragraph></td><td styleCode=" Botrule Lrule Rrule " valign="top"><paragraph>every 6 hours</paragraph></td></tr><tr><td colspan="5" styleCode=" Botrule Lrule Rrule " valign="top"><sup>1.</sup> Patients weighing less than 40 kg (88 lbs) </td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.